Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements

Download results of this page

Refine by:

Content type

Project (20)

Advanced search

Search projects and results

Results 1 - 10 of 20
12 > 
Mobile Filovirus Nucleic Acid Test
ID: 115848
Start date: 2015-02-01, End date: 2017-04-30
We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics...
Programme: H2020-EU.
Record Number: 209448
Last updated on: 2017-04-05
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
ID: 115842
Start date: 2015-03-01, End date: 2018-02-28
The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates...
Programme: H2020-EU.
Record Number: 209443
Last updated on: 2017-03-27
Models Of Patient Engagement for Alzheimer’s Disease
ID: 115985
Start date: 2016-12-08, End date: 2019-11-30
The MOPEAD consortium has proposed a programme of work carefully aligned to the objectives of IMI2 Call to deliver a step-change in AD-related patient engagement (PE) strategies and a paradigm shift in early stage care. It aims to improve patient engagement in two categories:...
Programme: H2020-EU.3.1.7.
Record Number: 209465
Last updated on: 2017-03-27
Patient Preferences in benefit risk assessments during the drug life cycle
ID: 115966
Start date: 2016-11-16, End date: 2021-09-30
The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i.e. in the early stages of identifying medical needs, in clinical testing, to guide decisions on reimbursement and to make decisions on...
Programme: H2020-EU.3.1.7.
Record Number: 209460
Last updated on: 2017-03-27
Amyloid imaging to Prevent Alzheimer’s Disease
ID: 115952
Start date: 2016-12-08, End date: 2021-09-30
Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary...
Programme: H2020-EU.3.1.7.
Record Number: 209458
Last updated on: 2017-03-27
Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
ID: 115976
Start date: 2017-01-10, End date: 2021-10-31
Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaques, fibrillary tau tangles, inflammation and neuronal loss. Phagocytes around amyloid plaques in late onset AD (LOAD) may be neurotoxic...
Programme: H2020-EU.3.1.7.
Record Number: 209462
Last updated on: 2017-03-27
Biomarker Enterprise to Attack DKD
[PROJECT] BEAt-DKD - Biomarker Enterprise to Attack DKD
ID: 115974
Start date: 2017-01-06, End date: 2021-08-31
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent or cure DKD. Apart from...
Programme: H2020-EU.3.1.7.
Record Number: 209459
Last updated on: 2017-03-27
Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development
ID: 115975
Start date: 2016-12-08, End date: 2019-09-30
APOEɛ4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect both the vasculature and the brain. This complexity and pleiotropic influence demands an integrated hypothesis-free approach to embark...
Programme: H2020-EU.3.1.7.
Record Number: 209461
Last updated on: 2017-03-27
Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
ID: 115916
Start date: 2015-12-18, End date: 2019-03-31
The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a...
Programme: H2020-EU.
Record Number: 209457
Last updated on: 2017-03-27
Vaccine lot to Vaccine lot comparison by consistancy testing
ID: 115924
Start date: 2016-04-28, End date: 2021-02-28
Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the level of product knowledge, production technology and quality management in those days. Current production techniques are optimised...
Programme: H2020-EU.
Record Number: 209456
Last updated on: 2017-03-27
12 > 
List retrieved on: 2017-04-30
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top